ClinicalTrials.gg
CompletedNCT00289536Updated Jun 10, 2021Results posted

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

A Phase 4 interventional study of Antihemophilic factor, recombinant, manufactured protein-free and Antihemophilic factor, recombinant, manufactured protein-free in Hemophilia A, sponsored by Baxalta now part of Shire. Completed at 8 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A — 1 open to participants now, 2 under way, none of them phase 3. antihemophilic factor, human recombinant · Hemophilia A.

Enrollment
12th of 21
38 · median 50
Started
2006
with 1 other
Phase 4
8 of 21
1 open now
Registered
5th of 21
by date
Lead sponsor
8 of 21
Baxalta now part of Shire

Among the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, this one is the 12th largest by enrollment, is one of 2 that started in 2006, is one of 8 in phase 4, and was the 5th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 21 studies testing antihemophilic factor, human recombinant in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About antihemophilic factor, human recombinant

antihemophilic factor, human recombinant: first FDA approval 1992 (Bioclate (Armour), Recombinate), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing antihemophilic factor, human recombinant in Hemophilia A, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic parameters. The 3 doses are 15, 30, and 50 IU/kg. Prior to each infusion, subjects will not have received treatment with a factor VIII concentrate for at least 3 days. Blood samples will be drawn within 30 minutes pre-infusion and at 0.25, 0.5, 1, 3, 6, 9, 24, 28, 32 and 48 hours post-infusion. A washout period of at least 3 days, but no more than 30 days between the last blood draw and the next infusion will be observed. During participation, subjects will maintain their preexisting treatment regimens with ADVATE rAHF-PFM or other factor VIII concentrate.

A secondary objective is to investigate the relationship between pharmacokinetic parameters at each dose level and the levels of von Willebrand factor ristocetin cofactor activity and von Willebrand factor antigen at baseline.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has severe hemophilia A as defined by a baseline factor VIII activity \<1% of normal; tested at screening. (A minimum of 3 days is required before the blood sample can be drawn to determine baseline factor VIII levels.)
  • The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant).
  • The subject is within 12 to 65 years of age.
  • The subject has a performance score >60.
  • The subject is negative (HIV-) or HIV+ with >=400 cells/mm3 (CD4 count determined at screening, if necessary).
  • The subject or subject´s legally authorized representative has provided written .

Exclusion criteria

Exclusion Criteria:

  • The subject has a known to mouse or hamster proteins or to factor VIII concentrates.
  • The subject has a history of factor VIII inhibitors with titer >=0.8 BU (Bethesda Assay) or >=0.4 BU (Nijmegen modification of the Bethesda Assay) any time prior to screening.
  • The subject has a detectable factor VIII inhibitor at screening, >=0.4 BU (Nijmegen modification of the Bethesda Assay), in the Baxter central laboratory.
  • The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: (INR) >1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.
  • The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g. qualitative defect or von Willebrand´s Disease).
  • The subject has participated in another study within 30 days of enrollment.
  • The subject´s clinical condition may require a major or moderate surgery (estimated blood loss >500 mL) during the period of participation in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Low Dose

    Biological: Antihemophilic factor, recombinant, manufactured protein-free

  • Experimental
    Medium Dose

    Biological: Antihemophilic factor, recombinant, manufactured protein-free

  • Experimental
    High Dose

    Biological: Antihemophilic factor, recombinant, manufactured protein-free

Interventions

06

What researchers measure

Primary outcomes

  1. Initial Recovery

    Percent increase in factor VIII concentration per dose from pre- to post-infusion

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion

Secondary outcomes

  1. Area Under the Curve/Dose

    Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  2. Terminal Half-life

    Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  3. Area Under the Curve

    AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  4. Total Area Under the Curve

    Total AUC with extrapolation using the slope of the β-phase

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  5. Total Area Under the Moment Curve

    Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  6. Weight-adjusted Clearance

    Computed as weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  7. Mean Residence Time

    Computed as total AUMC divided by total AUC

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  8. Volume of Distribution at Steady State

    Computed as weight-adjusted CL \* Mean Residence Time

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  9. Maximum Plasma Concentration

    Maximal factor VIII concentration after infusion

    Time frame: Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion

  10. Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)

    Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.

    Time frame: At baseline and before each pharmacokinetic evaluation

  11. Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)

    Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.

    Time frame: At baseline and before each pharmacokinetic evaluation

07

Results

Posted Jan 13, 2011

Participant flow

Recruitment was conducted in the United States at 8 study sites.

Period 1
Participant flow — Period 1
MilestoneLow DoseMedium DoseHigh Dose
Started989
Completed989
Not completed000
Period 2
Participant flow — Period 2
MilestoneLow DoseMedium DoseHigh Dose
Started1097
Completed1097
Not completed000
Period 3
Participant flow — Period 3
MilestoneLow DoseMedium DoseHigh Dose
Started7910
Completed799
Not completed001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryInitial Recovery

Percent increase in factor VIII concentration per dose from pre- to post-infusion

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion to 30 minutes post-infusion
Reported as:
Median · IU/dL per IU/kg
Initial Recovery
IU/dL per IU/kgLow DoseMedium DoseHigh Dose
Initial Recovery1.7 (0.5 to 2.7)1.6 (0.4 to 2.6)1.8 (1.2 to 2.8)
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · ANOVA · p = 0.1662Repeated measures ANOVA with dose as fixed effect
SecondaryArea Under the Curve/Dose

Area under the plasma factor VIII concentration versus time curve (AUC) estimated by linear trapezoidal method per dose.

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · IU*hour/dL per IU/kg
Area Under the Curve/Dose
IU*hour/dL per IU/kgLow DoseMedium DoseHigh Dose
Area Under the Curve/Dose21.2 (8.8 to 43.3)20.5 (6.5 to 42.2)22.3 (14.5 to 46.9)
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · ANOVA · p = 0.0965 (No adjustments were made for multiple comparisons.)Repeated measures ANOVA with dose as fixed effect
SecondaryTerminal Half-life

Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · hour
Terminal Half-life
hourLow DoseMedium DoseHigh Dose
Terminal Half-life11.3 (5.4 to 19.9)12.3 (6.0 to 20.0)11.2 (7.5 to 25.1)
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · ANOVA · p = 0.5057Repeated measures ANOVA with dose as fixed effect
SecondaryArea Under the Curve

AUC estimated by linear trapezoidal method. The linear trapezoidal method is a numerical method used to approximate the area under a curve.

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · IU*hour/dL
Area Under the Curve
IU*hour/dLLow DoseMedium DoseHigh Dose
Area Under the Curve300.1 (124.5 to 544.9)595.2 (167.8 to 1104.8)1055.8 (712.1 to 1778.3)
SecondaryTotal Area Under the Curve

Total AUC with extrapolation using the slope of the β-phase

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · IU*hour/dL
Total Area Under the Curve
IU*hour/dLLow DoseMedium DoseHigh Dose
Total Area Under the Curve318.5 (131.8 to 648.8)616.3 (194.4 to 1264.8)1116.0 (723.3 to 2344.9)
SecondaryTotal Area Under the Moment Curve

Total area under the first moment curve (AUMC) estimated by linear trapezoidal methods

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · IU*hour^2/dL
Total Area Under the Moment Curve
IU*hour^2/dLLow DoseMedium DoseHigh Dose
Total Area Under the Moment Curve4760.9 (1042.9 to 16315.9)7115.1 (2673.6 to 28374.2)16464.7 (7111.4 to 77439.7)
SecondaryWeight-adjusted Clearance

Computed as weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · mL/kg*hour
Weight-adjusted Clearance
mL/kg*hourLow DoseMedium DoseHigh Dose
Weight-adjusted Clearance4.71 (2.34 to 11.38)4.88 (2.37 to 15.43)4.47 (2.13 to 6.91)
SecondaryMean Residence Time

Computed as total AUMC divided by total AUC

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · hour
Mean Residence Time
hourLow DoseMedium DoseHigh Dose
Mean Residence Time14.6 (7.2 to 25.1)12.8 (7.5 to 24.7)14.7 (9.2 to 33.0)
SecondaryVolume of Distribution at Steady State

Computed as weight-adjusted CL \* Mean Residence Time

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · dL/kg
Volume of Distribution at Steady State
dL/kgLow DoseMedium DoseHigh Dose
Volume of Distribution at Steady State0.7 (0.4 to 0.9)0.6 (0.4 to 3.4)0.6 (0.3 to 0.8)
SecondaryMaximum Plasma Concentration

Maximal factor VIII concentration after infusion

Time frame:
Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion
Reported as:
Median · IU/dL
Maximum Plasma Concentration
IU/dLLow DoseMedium DoseHigh Dose
Maximum Plasma Concentration26.0 (13.0 to 42.0)50.0 (14.0 to 79.0)93.0 (65.0 to 143.0)
SecondaryPre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)

Percentage of normal VWF:Rco activity. Normal is a lab standard consisting of a non-hemophilic population. Relationships between baseline VWF:Rco and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.

Time frame:
At baseline and before each pharmacokinetic evaluation
Reported as:
Median · Percent of normal VWF:Rco activity
Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)
Percent of normal VWF:Rco activityLow DoseMedium DoseHigh Dose
Pre-infusion Von Willebrand Factor Ristocetin Cofactor Activity (VWF:Rco)83.0 (40 to 152)80.5 (49 to 186)80.5 (33 to 182)
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = 0.7048 (No adjustments were made for multiple comparisons.)
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = .0322 (No adjustments were made for multiple comparisons.)
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = 0.0056 (No adjustments were made for multiple comparisons.)
SecondaryPre-infusion Von Willebrand Factor Antigen (VWF:Ag)

Percentage of VWF:Ag. Relationships between baseline VWF:Ag and pharmacokinetic parameters (initial recovery, total AUC/dose, and half-life) were evaluated statistically.

Time frame:
At baseline and before each pharmacokinetic evaluation
Reported as:
Median · U/dL
Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)
U/dLLow DoseMedium DoseHigh Dose
Pre-infusion Von Willebrand Factor Antigen (VWF:Ag)103.0 (57 to 307)117.0 (63 to 309)109.5 (61 to 329)
Statistical analysis
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = 0.3696 (No adjustments were made for multiple comparisons.)
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = 0.0001 (No adjustments were made for multiple comparisons.)
  • Low Dose vs Medium Dose vs High Dose · Regression, Linear · p = <0.0001 (No adjustments were made for multiple comparisons.)

Adverse events

Collected over 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population (26 Participants)—0/26 (0%)4/26 (15.4%)
Most frequent other events
Most frequent other events
EventSafety Population (26 Participants)
HeadacheNervous system disorders3/26
Pain in extremityMusculoskeletal and connective tissue disorders2/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treated Participants
<=18 years7
Between 18 and 65 years19
>=65 years0
Age, Continuous
Age, Continuous(years)Treated Participants
Mean23.8 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Treated Participants
Female0
Male26
Region of Enrollment
Region of Enrollment(Participants)Treated Participants
United States26
08

Study locations

8 sites
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Peoria, Illinois, United States
  • Iowa City, Iowa, United States
  • New Brunswick, New Jersey, United States
  • Cincinnati, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Houston, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2006 to primary completion in Apr 2007, 13 months.

Results were first posted in Jan 2011, 3 years 9 months after primary completion.

Of 40 phase 4 interventional studies under Hemophilia A, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 112. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2006
First posted
Feb 10, 2006
StartActual
Feb 2, 2006
Primary completionActual
Apr 1, 2007
CompletionActual
Apr 1, 2007
Results first posted
Jan 13, 2011
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00289536
Responsible party
Sponsor
First posted
Feb 10, 2006
Start date
Feb 2, 2006
Primary completion
Apr 1, 2007
Completion
Apr 1, 2007
Results posted
Jan 13, 2011
Last update
Jun 10, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antihemophilic factor, human recombinant · F8 protein, human

Start the discussion